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The ADA genes encode factors which are proposed to function as transcriptional coactivators. Here we
describe the cloning, sequencing, and initial characterization of a novel ADA gene, ADA1. Similar to the
previously isolated ada mutants, ada1 mutants display decreases in transcription from various reporters.
Furthermore, ADA1 interacts with the other ADAs in the ADA/GCN5 complex as demonstrated by partial
purification of the complex and immunoprecipitation experiments. We estimate that the complex has a
molecular mass of approximately 2 MDa. Previously, it had been demonstrated that ada5 mutants displayed
more severe phenotypic defects than the other ada mutants (G. A. Marcus, J. Horiuchi, N. Silverman, and L.
Guarente, Mol. Cell. Biol. 16:3197–3205, 1996; S. M. Roberts and F. Winston, Mol. Cell. Biol. 16:3206–3213,
1996). ada1 mutants display defects similar to those of ada5 mutants and different from those of the other
mutants with respect to promoters affected, inositol auxotrophy, and Spt2 phenotypes. Thus, the ADAs can be
separated into two classes, suggesting that the ADA/GCN5 complex may have two separate functions. We
present a speculative model on the possible roles of the ADA/GCN5 complex.
RNA polymerase II (Pol II)-dependent transcription in eu-
karyotes requires general transcription factors and gene-spe-
cific transcriptional activators. The general factors include Pol
II itself, the TATA binding protein (TBP), TFIIB, and other
factors required for preinitiation complex formation at pro-
moters. Activators bind to upstream activating sequences
(UAS) or enhancers, which can be hundreds of base pairs
upstream from the site of initiation of transcription, and stim-
ulate transcription through their activation domains. In addi-
tion to these two types of factors, a third type whose members
are referred to as mediators, coactivators, or adaptors has been
isolated (3, 32, 44). These have been proposed to function by
several mechanisms, including bridging interactions between
activator proteins and basal factors and counteracting of the
repressive effects on transcription by nucleosomes. Many fac-
tors believed to belong to this coactivator group form large
heteromeric complexes. For example, the SWI/SNF complex is
approximately 2 MDa in size (11, 40, 60) and functions by
countering chromatin-mediated repression (14, 27). The sup-
pressor of RNA polymerase B (SRB) complex is required for
robust activated and basal transcription and interacts with
basal factors to form an RNA Pol II holoenzyme complex (25,
35, 58). The TFIID complex consists of basal transcription
factor TBP and associated TAF proteins which are thought to
be required for activated transcription (15, 51, 59).
Two other groups of factors which seem to function as adap-
tors or coactivators, the SPTs and the ADAs, were identified
genetically in Saccharomyces cerevisiae. The SPT genes were
isolated as suppressors of the auxotrophies resulting from
transposon insertions at the promoters of various biosynthetic
genes. The SPT genes fall into two classes based upon the
insertions that they suppress and upon various other genetic
and molecular characteristics (61). One class is the histone
class, which includes SPT4, SPT5, SPT6, SPT11, and SPT12.
SPT11 and SPT12 encode histones H2A and H2B, respectively.
SPT4, SPT5, and SPT6 also encode negative regulators of
transcription that form a complex and that are thought to be
functionally related to H2A and H2B (57). The second class,
the TBP class, includes SPT3, SPT7, SPT8, SPT15, and SPT20.
SPT15 encodes TBP, while the others encode products which
are thought to interact with TBP and to play a role in tran-
scriptional-initiation site selection (16, 17, 61).
The ADA genes were isolated as suppressors of GAL4-VP16
toxicity (4). When GAL4-VP16 is overexpressed, it is thought
to kill yeast cells by sequestering the general transcription
factors away from productive transcription complexes. There-
fore, mutations that suppress toxicity may be in genes encoding
factors that mediate the interaction between the general fac-
tors and activation domains. The ada mutants fell into five
complementation groups, four of which have been character-
ized, ADA2, ADA3, GCN5, and ADA5 (4, 37, 38, 43). GCN5
had been previously isolated as a gene whose product was a
factor required for full transcriptional activation by GCN4
(21). ADA3 has been subsequently isolated as NGG1, a gene
whose product is required for glucose repression (5, 6).
ADA2, ADA3, and GNC5 are all required for full transcrip-
tional activation by a subset of activators, including GAL4-
VP16 and GCN4 (4, 38, 43). This is consistent with a model in
which these ADAs function as adaptors for a subset of activa-
tors. Also, mutations in the three genes yield similar pheno-
types, such as temperature sensitivity and slow growth. Mu-
tants carrying null alleles of any two of the three genes display
phenotypes identical to those of single mutants (20, 38). It has
been demonstrated that ADA2, ADA3, and GCN5 interact to
form a complex (12, 29, 38).
ADA5 is similar to the other ADAs except that mutations
result in some broader transcriptional defects (37, 45). For
example, the ADH1 promoter is not affected by mutations in
ADA2, ADA3, or GNC5 but is reduced in ada5 mutants. Fur-
thermore, ADA5 has been shown to be identical to SPT20
linking the ADA genes and the SPT genes (45). The other
ADAs have not been isolated as spt mutants and do not display
* Corresponding author. Phone: (617) 253-6965. Fax: (617) 253-
8699.
3220
Spt2 phenotypes. Despite these differences, Dada5 Dada3 mu-
tants do not demonstrate any phenotypes more severe than
that of a DADA5 mutant. Furthermore, there is evidence that
ADA5 interacts with ADA3 (37), suggesting that it too is part
of an ADA/GCN5 complex.
Recently, a functional role for the ADA/GCN5 complex has
been suggested. A histone acetyltransferase activity has been
purified from Tetrahymena macronuclei (7). The gene respon-
sible for this activity was cloned and was determined to be a
homolog of GCN5 (10). Yeast GCN5 has also been shown to
have histone acetyltransferase activity. Combined with data
that ADA2 and ADA5 interact with activators (2, 37, 39, 55),
this suggests that the role of the ADA/GCN5 complex may be
to acetylate nucleosomes at transcriptionally active sites (8).
In this study, we describe the cloning and characterization of
a novel ADA gene, ADA1. We present evidence that ADA1 is
part of a large ADA/GCN5 complex and that ada1 mutants
display phenotypes similar to that of ada5 and broader than
those of ada2, ada3, and gcn5 mutants. Thus, although the
ADA proteins bind to form a complex, they can be separated
into two classes, suggesting that the ADA/GCN5 complex may
have a second function in addition to histone acetylation.
MATERIALS AND METHODS
Strains and media. Strains used in this study are shown in Table 1. BWG1-7a,
1-7aDada1, and 1-7aDada2 were used for purification and immunoprecipitation
experiments. BWG1-7a, 1-7aDada1, PSY316, and 316Dada1 were used for b-ga-
lactosidase assays. Inositol studies were performed with PSY316 and PSY316 in
which the appropriate ADA gene was disrupted. Strains FY56, FY710, and
FY630, used to determine Spt phenotypes, were gifts from S. Roberts and F.
Winston. Disruptions of ADA1 in yeast cells were generated by transforming the
appropriate strains with pADA1KO (described below) that had been linearized
with XhoI. ADA3 was deleted with pADA3KO (38). Disruptions were verified by
Southern analysis.
Rich, synthetic complete, and synthetic minimal media were prepared as
previously described (53).
Cloning and sequencing of ADA1. Three original clones complementing the
slow-growth, morphological-defect, and GAL4-VP16-resistance phenotypes of
the ada1-1 mutant (4) were originally isolated. One clone, YCP50ADA1, had an
11-kb insert. Two others had identical 16-kb inserts. Physical mapping with
restriction enzymes revealed that these clones overlapped over a region of 5.7 kb.
This region had a convenient HindIII site. By using a second HindIII site in the
vector (YCP50) and a third in a nonoverlapping region in YCP50ADA1, the
5.7-kb region was split into two fragments which were separately subcloned into
YCP50. Neither subclone complemented the slow-growth phenotype of the
ada1-1 mutant, suggesting that the relevant gene had been cut in half. The
HindIII fragments were subcloned into pBluescript (Stratagene) and sequenced
from the internal HindIII site. Sequencing was performed by the dideoxy chain
termination method (49). Further sequence was obtained by either subcloning
convenient restriction fragments into pBluescript or using custom synthetic oli-
gonucleotide primers. This revealed an open reading frame of 488 codons (later
verified as ADA1) with an internal HindIII site.
Plasmid constructions. PCR primers were designed such that the coding
region of ADA1 could be amplified with BamHI and AflIII sites on the 59 end and
a six-histidine tag followed by a stop codon and a BamHI site on the 39 end of the
gene. The PCR product was digested with BamHI and ligated into the BamHI
site of pBluescript to generate BluescriptADA1. The BluescriptADA1 BamHI
fragment was cloned into the BglII site of DB20LeuBgl (4) to generate
DB20LADA1.
To verify that the cloned ADA1 gene actually corresponded to the gene that was
mutated in the ada1-1 strain, it was necessary to mark the genomic locus of the
cloned gene. The BamHI fragment from DB20LADA1 which contained the cloned
gene under control of the ADH1 promoter was inserted into the BamHI site in
pRS306 (54), a URA3-marked integrating plasmid. This construct was digested with
BclI to direct integration to the cloned locus and was used as described in Results.
The disruption construct of ADA1, pADA1KO, was generated in several steps.
Vector pUC19Xho-Hind was constructed by inserting an XhoI linker into the
SmaI site of pUC19 and destroying the HindIII site by cutting, filling in with
Klenow fragment, and ligating. A 5.4-kb XhoI fragment containing the coding
and flanking sequences of ADA1 was digested from YCP50ADA1 and ligated
into the XhoI site of pUC19Xho-Hind. This was subsequently digested with
HindIII and EcoRV, filled-in with Klenow fragment, and ligated to a BglII linker.
The hisG-URA3 cassette from pNKY51 (1) was ligated into the BglII site. This
construct disrupts ADA1 between the codons for amino acids 113 and 408.
For recombinant expression of ADA1, the bacterial expression vector
pUHE24.2DCAT (38) was used. The ADA1 coding region fused to a six-histidine
tag was digested from BluescriptADA1 with AflIII and BamHI. This fragment
was cloned into the NcoI and BamHI sites of pUHE24.2DCAT to generate
pUHE24.2ADA1.
For recombinant expression of GCN5, the GCN5 coding sequence was am-
plified by PCR with primers GCN5N and GCN5C (38). The product was digested
with EcoRI and NotI and cloned into the EcoRI and NotI sites of pET28a
(Novagen). The resulting plasmid, pET28a-EcoGCN5, could be used to express
a carboxyl-terminal fragment of GCN5 with a six-histidine tag at its amino-
terminal end.
To make plasmid pPADA26HIS, pDB200CADA26HIS, an ARS-CEN deriv-
ative of pADA26HIS (55), was digested with SpeI, filled in with T4 DNA poly-
merase, and then digested with AflII. The fragment that contained the C-termi-
nal one-third of ADA2 fused to a six-histidine tag and that was followed by the
ADH1 terminator was purified and cloned into pNS3.8 (4) that had been digested
with AflII and MscI. This created a plasmid which contained the ADA2 promoter
expressing the ADA2-six-histidine fusion gene followed by the ADH1 terminator.
Yeast manipulations. Transformations were performed by the lithium acetate
method (53). For b-galactosidase assays, cells were grown to an optical density at
600 nm of approximately 1.0 and activity was measured in glass bead extracts as
previously described (46). Cells were grown in synthetic complete medium lack-
ing uracil. For HIS(2)14x2 and HIS(1)66 activity, cells were induced in minimal
media complemented only for the auxotrophies of the yeast for 8 h. b-Galacto-
sidase activity was measured as nanomoles per minute per milligram of protein.
Reporters used were pLGDAluXho (22) for CYC1 UAS1, which binds the
activator HAP1; pLG265UP1 (18) for CYC1 UAS2, which binds the HAP2/3/4/5
heterotetrameric activator; HIS(1)66 (26) and HIS(2)14x2 (26), which bind
GCN4; pCP0 (50), which contains the ADH1 promoter; and pdAT2 (36), which
contains the thymidine-rich UAS of the DED1 gene. Other general yeast tech-
niques were performed according to standard protocols (23).
Generation of antisera. pUHE24.2ADA1 was transformed into AG115 (30)
cells. Cells were grown to an optical density of 0.5, induced with 2 mM isopropyl-
b-D-thiogalactopyranoside, and grown for another 2 h. Cells were lysed by son-
ication, and the insoluble material, which contained recombinant ADA1 fused to
a six-histidine tag, was resuspended in 8 M urea. Recombinant ADA1 was
purified on a Ni-nitrilotriacetic acid (NTA) agarose column (Qiagen) as recom-
mended by the manufacturer.
To obtain polyclonal antisera to ADA1, 1 mg of recombinant ADA1 was
dialyzed into 2 ml of phosphate-buffered saline solution, mixed with adjuvant
(RIBI ImmunoChem Research, Inc.), and injected into two rabbits according to
standard protocols (24). After several boosts, antibodies to ADA1 were purified
from crude serum by binding to immunoblots of recombinant ADA1 and eluting
at pH 2.5 or by binding and eluting from recombinant ADA1 cross-linked to
cyanogen bromide-activated Sepharose beads.
In order to generate antibodies to GCN5, a carboxyl-terminal fragment of
GCN5, tagged with six histidines, was purified in a manner similar to that for
ADA1 above, except that plasmid pET28a-EcoGCN5 and strain BL21:DE3
(Novagen) were used. The eluate from the Ni-NTA agarose column was sub-
jected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE), and acrylamide slices containing the GCN5 protein fragment were
TABLE 1. Strains used in this study
Strain Genotype Source orreference
ada1-1 MATa ura3-52 leu2-3,112 his4-519
ade1-100 gal4::HIS4 ada1-1
4
BWG1-7a MATa ura3-52 leu2-3,112 his4-519
ade1-100
Laboratory strain
1-7aDada1 BWG1-7a Dada1::hisG This study
1-7aDada2 BWG1-7a Dada2::hisG 4
PSY316 MATa ura3-52 leu2-3,112 his3-D200
ade2-101 lys2-801
Laboratory strain
316Dada1 PSY316 Dada1::hisG This study
316Dada2 PSY316 Dada2::hisG 4
316Dada3 PSY316 Dada3::hisG 34
GMy27 PSY316 Dgcn5::hisG 34
FY56 MATa ura3-52 LEU2 his4-912d
lys2-128d
Fred Winston
FY56Dada1 FY56 Dada1::hisG This study
FY56Dada3 FY56 Dada3::hisG This study
FY710 MATa ura3-52 leu2D1 his4-912d
lys2-128d D(hta1-htb1)::LEU2
Fred Winston
FY630 MATa ura3-52 leu2D1 his4-917d
lys2-173R2 trp1D63
Fred Winston
FY630Dada1 FY630 Dada1::hisG This study
FY630Dada3 FY630 Dada3::hisG This study
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lyophilized and resuspended in phosphate-buffered saline. Antibodies to GCN5
were generated as described for ADA1 except that 400 mg of protein was injected
into each rabbit. Antibodies to ADA2 (38), ADA3 (37), ADA5 (37), TBP, and
TFIIB (33) have been described previously.
Extracts and fractionation. The purification of the ADA/GCN5 complex was
performed in 1-7aDada2 (4) carrying pPADA26HIS. Cells were grown in mini-
mal media to yield an approximate wet weight of 500 g. Preparation and frac-
tionation of whole-cell extract on a Bio-Rex 70 column (5 by 10 cm) were
performed as described by others (52) except elutions were performed with 250,
600, and 1,200 mM potassium acetate. Elutions were analyzed for the presence
of ADA2 and ADA3 proteins by Western blotting. The relevant fractions from
the 600 mM potassium acetate elutions were pooled and dialyzed against a buffer
containing 20 mM HEPES (pH 7.6), 10% glycerol, 300 mM potassium acetate,
10 mM b-mercaptoethanol, and protease inhibitors. This material was then
bound to an Ni-NTA agarose column (1.5 by 10 cm) and eluted with an imidazole
gradient. Fractions enriched in ADA2 and ADA3 were pooled and diluted into
buffer H (20 mM HEPES [pH 7.6], 10% glycerol, 1 mM dithiothreitol, 1 mM
EDTA, protease inhibitors) to a final salt concentration of 100 mM potassium
acetate. This material was then fractionated over a Poros HQ-20 column (4.6 by
100 mm) (PerSeptive Biosystems) with an elution gradient from 100 to 1,500 mM
potassium acetate of 10 column volumes by using the BioCAD Sprint apparatus
(PerSeptive Biosystems). Fractions that contained the peak of ADA proteins
were pooled and loaded onto a Superose 6 HR 10/30 gel filtration column
(Pharmacia Biotech). The column was then washed with buffer H containing 300
mM potassium acetate, and fractions were collected. As a control for determin-
ing the approximate molecular weight of the ADA/GCN5 complex, protein size
standards (Bio-Rad) were fractionated on the Superose 6 column under identical
conditions.
For quantifying purification, a densitometer (LKB) was used to measure the
relative band intensities on immunoblots of ADA2, ADA3, and ADA1.
Immunoprecipitations. Preparation and fractionation of extracts of BWG1-7a
and 1-7aDada1 were performed as described previously (37). Cross-linking of
antisera to protein A-Sepharose beads and immunoprecipitation experiments
were also performed according to published methods (11) except that 1 ml of the
600 mM eluate from the Bio-Rex 70 column was used for the precipitations and
except that bound material was eluted off the antisera-coated beads with 20 ml of
50 mM glycine (pH 2.5), neutralized with 3 ml of 1 M Tris (pH 7.5), and mixed
with 43 SDS-PAGE loading buffer.
Nucleotide sequence accession number. The sequence of ADA1 has been
assigned GenBank accession no. U76735; that of the sequence of HFI1, a gene
identical to ADA1, is U41324 (19).
RESULTS
Cloning and sequencing of ADA1. ada mutants were isolated
from a screen for GAL4-VP16-resistant mutants as previously
described (4), with the exception that the first ada1 allele,
ada1-1, was isolated from nonmutagenized cells. The ada1
mutants isolated have severe slow-growth defects and morpho-
logical changes (28). These phenotypes are recessive. We
therefore used the slow-growth phenotype of ada1-1 to isolate
complementing clones from a yeast genomic library on an
ARS-CEN-containing vector (4, 42). Three overlapping clones
which not only restored wild-type growth but also restored
wild-type morphology and sensitivity to overexpressed GAL4-
VP16 were isolated. By analyzing the complementation of sub-
clones and sequencing, a putative open reading frame of 488
codons was identified (see Materials and Methods). The puta-
tive open reading frame was amplified by PCR and cloned into
an episome under the control of the ADH1 promoter (see
Materials and Methods). This construct also complemented
the slow-growth phenotype, restored wild-type morphology,
and restored sensitivity to GAL4-VP16 overexpression. To ver-
ify that the cloned gene corresponded to ADA1, the URA3
marker was integrated at the cloned locus in a wild-type strain
(see Materials and Methods) and mated to ada1-1. The result-
ant diploid was sporulated, and in six of six four-spore tetrads
tested, resistance to GAL4-VP16 toxicity segregated 2:2 in
opposition to the Ura1 phenotype. It was determined through
database searches that a gene identical to ADA1, termed HFI1,
had been cloned (19). There are no other genes with any
significant homologies to ADA1.
ADA1 was deleted in yeast cells as described in Materials
and Methods. The deletion mutant was similar to ada1 other
mutants with respect to slow growth and resistance to GAL4-
VP16 toxicity. Both phenotypes were fully complemented by
the cloned gene. The morphological changes for ada1 mutants
mentioned above were determined to be strain specific. Dis-
rupting ADA1 in BWG1-7a resulted in extremely elongated
cells, similar to the morphology of the original ada1-1 mutant,
which was in a BWG1-7a background. Disrupting ADA1 in
PSY316 resulted in a slight change in cell morphology which
was much less apparent than that in BWG1-7a.
ada1 mutants display transcriptional defects. Consistent
with a model in which the ADA proteins function as transcrip-
tional coactivators or adaptors, the ADAs isolated previously
have specific defects in transcription (4, 37, 38, 43). In order to
determine whether Dada1 strains were also defective for tran-
scription from certain activators, b-galactosidase assays were
performed on wild-type and Dada1 strains transformed with
various reporters. As demonstrated in Table 2, Dada1 strains
show decreased activity from several reporters. The activities
of reporters which bind activators HAP1 (CYC1 UAS1) and
HAP2/3/4/5 (CYC1 UAS2UP1) were reduced 21- and 9-fold,
respectively, and those of reporters which bind the activator
GCN4, HIS(1)66 and HIS(2)14x2, were reduced 15- and 34-
fold, respectively. The activity of the ADH1 reporter was also
reduced fivefold in a Dada1 strain. This is of particular interest
because the Dada2, Dada3, and Dgnc5 strains do not show this
decrease (4, 38), while Dada5 strains do (37). These results
suggest that the ADA genes can be separated into two classes
based upon transcriptional differences. The activity of a re-
porter containing the thymidine-rich sequences of the DED1
gene as a UAS, dAdT, was not reduced in a Dada1 strain. In
fact, activity may have been slightly elevated. This argues that
it is not a general defect in transcription that occurs in Dada1
strains but rather specific defects that affect only a subset of
promoters.
ada1 mutants are auxotrophic for inositol and display Spt2
phenotypes. Mutations in many factors that are thought to be
coactivators result in inositol auxotrophy. These include the
SRB genes (34), the SWI/SNF genes (41), and some SPT genes,
including ADA5/SPT20 (45). In order to determine whether
deleting ADA1 resulted in inositol auxotrophy, various strains
were grown on plates lacking inositol. As shown in Fig. 1, a
Dada1 strain does not grow on media lacking inositol, whereas
Dada2, Dada3, and Dgcn5 strains do. This further links ADA1
to ADA5 phenotypically and separates them from ADA2,
ADA3, and GCN5.
To determine whether ada1 mutants displayed other pheno-
types similar to that of ada5/spt20 mutants, we tested whether
Dada1 strains displayed an Spt2 phenotype. ADA1 was dis-
rupted in strain FY56, which contains d element insertions at
TABLE 2. b-Galactosidase assaysa of wild-type and Dada1 strains
Reporter
Activity (nmol/min/mg of protein)
of strain:
wtb Dada1
CYC1 UAS1 144 6.7
CYC1 UAS2up1 265 28
HIS(1)66 8160 547
HIS(2)14x2 2990 89
ADH1 12800 2400
dAdT 319 627
a Assays were performed as described in Materials and Methods. Measure-
ments are the averages of assays performed on four individual transformants.
Standard errors were less than 20% of the means.
b wt, wild type.
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the HIS4 and LYS2 loci. As demonstrated in Fig. 2A, a DADA1
mutant was indeed able to suppress the his4-912d and lys2-128d
alleles present in yeast strain FY56. In contrast, a DADA3
mutant was unable to suppress these alleles, further delineat-
ing the two classes of ADA genes. As a positive control, strain
FY710 (hta1 htb1D) was also able to suppress both the his4-
912d and lys2-128d alleles.
As mentioned previously, the SPT genes can be separated
into two classes: the histone class and the TBP class. Paradox-
ically, ADA5 had been isolated as an SPT of the TBP class (45),
while GCN5 has been shown to acetylate histones (10). Thus,
we were interested in knowing whether ADA1 is of the TBP or
histone class of SPTs. Since the his4-912d and lys2-128d alleles
do not distinguish between the two classes, ADA1 and ADA3
were disrupted in strain FY630, which contains his4-917d, an
allele specifically suppressed by the TBP class but not the
histone class. As demonstrated in Fig. 2B, a mutant with a
deletion of ADA1 was able to suppress the his4-917d allele
while a mutant with a deletion of ADA3 was not. This demon-
strates that ADA1 is of the TBP class of SPT genes.
FIG. 1. Inositol phenotype of a Dada1 strain. 316Dada1, 316Dada2, 316Dada3, GMy27 (316Dgnc5), and, as a positive control, 316Dada1 transformed with
YCP50ADA1 (Dada11ADA1) were grown on synthetic complete media lacking inositol (2Inositol) and on an identical plate on which 200 ml of 200 mM inositol had
previously been spread (1Inositol).
FIG. 2. Spt2 phenotype of a Dada1 strain. (A) The indicated strains were streaked on synthetic complete media (Complete) or media lacking lysine (2lysine) or
histidine (2histidine) to determine whether they suppressed the his4-912d and lys2-128d alleles present. FY710, for which the histone hta1-htb1 locus is disrupted, was
used as a positive control. (B) The indicated strains were patched on synthetic complete media (Complete) or on media lacking histidine (2histidine) to determine
whether they suppressed the his4-917d allele, which is specifically suppressed by mutants in the TBP class of SPTs.
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Partial copurification of an ADA complex. 1-7aDada2 was
transformed with pPADA26His, a plasmid which expresses a
six-histidine-tagged version of ADA2 from its own promoter
and which fully complements a deletion of the gene (56). The
resulting strain was grown in minimal media and was used to
make a whole-cell extract which was fractionated over a Bio-
Rex 70 column (see Materials and Methods). After step elu-
tion with potassium acetate, the ADA proteins were detected
by Western blot analysis in two fractions: the 600 mM fraction
and the 1,200 mM fraction. The 600 mM fraction contained
about 60% of the ADA proteins, and the 1,200 mM fraction
accounted for the remainder (56). We estimate that both the
600 and 1,200 mM eluent fractions represent a 10-fold purifi-
cation of the ADA/GCN5 complex (Table 3).
Next, the 600 mM eluent was bound to a Ni-NTA agarose
column. The Ni-NTA column was eluted with a gradient of
imidazole, and the ADA proteins were quantitatively recov-
ered in the peak fractions of the eluent. This step represented
only a 1.6-fold purification of the ADA/GCN5 complex (56)
because a relatively large fraction of proteins in the yeast
extract bound to the column under the conditions we used.
The peak fractions eluted from the Ni-NTA column were
fractionated on an HQ-20 anion-exchange column and were
eluted with a gradient of potassium acetate. As shown in Fig.
3, cofractionation of ADA1, ADA2, ADA3, GCN5, and ADA5
was observed. The peak of the ADA/GCN5 complex eluted
from the column at approximately 1.1 M potassium acetate.
The ADA proteins were purified approximately 160-fold in the
peak fractions from this column (Table 3). The fractions eluted
from the HQ-20 column were also probed for the basal tran-
scription factor, TBP. While TBP was present in the material
loaded onto the column, it did not cofractionate with the ADA
complex (Fig. 3) and, in fact, flowed through the column.
Fractions from the HQ-20 column were also probed with an-
tibodies to other transcription factors. TFIIB and TFIIE be-
haved similarly to TBP and flowed through the column, while
SRB4, SRB5, SWI3, and TFIIH fractionated together, eluting
prior to the ADA/GCN5 complex (56).
Finally, the fractions from the HQ-20 column containing the
peak amounts of ADA proteins were pooled and subjected to
fractionation on a Superose 6 gel filtration column. Again, all
ADA proteins cofractionated over this column (Fig. 4). A
comparison of the elution profiles of the ADA proteins with
those of known protein standards indicated that the ADA
proteins eluted at an approximate molecular mass of 2 MDa.
Use of the sizing column resulted in an 18-fold purification of
the ADA proteins, bringing the total purification to approxi-
mately 2,880-fold (Table 3). These data suggest that the ADA
gene products, including GCN5, form a complex in yeast.
Fractionation of the 1,200 mM potassium acetate elution
from the Bio-Rex 70 column on either an HQ-20 column or a
Superose 6 column also resulted in cofractionation of all five
ADA proteins (56).
ADA1 interacts with the ADA complex by immunoprecipi-
tation. In order to verify that ADA1 interacts with the other
ADAs, whole-cell extracts were made from wild-type and
Dada1 strains grown in rich media. The extracts were then
passed over a Bio-Rex 70 column, and the flowthrough and
250, 600, and 1,200 mM potassium acetate elutions were ex-
amined by Western blotting. As demonstrated in Fig. 5A,
ADA1 eluted from this column in a profile identical to that of
ADA3. The band that is seen in the 600 mM fraction of the
Dada1 strain is a background band that migrated at a slightly
higher molecular weight than that of ADA1 (compare wt and
Dada1 START lanes in the ADA1 Western blot of Fig. 5B). In
contrast to the partial purification of the ADA/GCN5 complex
FIG. 3. Cofractionation of ADA1, ADA2, ADA3, GCN5, and ADA5 over an
HQ-20 anion-exchange column. All panels show immunoblots of fractions from
the HQ-20 column eluted with a potassium acetate gradient. The onput (OP)
and flowthrough (FT) and every odd-numbered fraction between fractions 13
and 23 were probed with antibodies to the indicated proteins. The band recog-
nized by the GCN5 antibody ran slightly faster than expected. It is possible that
GCN5 was slightly degraded in our extracts.
FIG. 4. Cofractionation of the ADA proteins over a Superose 6 gel filtration
column. Aliquots of the onput (OP) to the column and the indicated fractions
were trichloroacetic acid precipitated and analyzed by Western blotting. Anti-
bodies to the indicated proteins were used to probe the blots. Aliquots corre-
sponded to 3% of the onput and 25% of the fractions.
TABLE 3. Partial purification of the ADA/GCN5 complex
Fraction
Protein (mg) in:
Yield
(%)
Fold
purificationa
Onput Pooledfractions Column Total
Crude extract 2975 100
Bio-Rex 70 2975 179.5 60 10 10
Ni-NTA agarose 149.5 72 38 1.6 16
Poros HQ-20 72 3.6 19 10 160
Superose 6 HRb 0.23 0.0004 0.03 18 2880
a The fold purification for a column is the ratio of the yield divided by the
protein in the pooled fractions of the column to that of the previous column. The
total fold purification at a particular column step is the product of that column’s
fold purification and the total fold purification for the previous column.
b The Superose 6 HR column was an analytical column with a low capacity and
yield.
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described above, some ADA1 and ADA3 was observed in the
flowthrough fraction. The flowthrough fraction was run over a
Superose 6 column, and all five ADA proteins cofractionated,
as determined by Western blotting (28), suggesting that the
column residue may have been limiting in this second prepa-
ration.
ADA1 was immunoprecipitated from the 600 mM potassium
acetate elutions from the Bio-Rex 70 column with ADA1 an-
tibodies cross-linked to protein A-Sepharose beads. As ex-
pected, antibodies to ADA1 were able to precipitate ADA1
from wild-type but not from Dada1 extracts and preimmune
antisera were unable to precipitate ADA1 from either extract
(Fig. 5B, ADA1 Western blot). As shown in the top portion of
Fig. 5B, ADA3 coimmunoprecipitated with ADA1, implying
that ADA1 and ADA3 interact. Importantly, ADA3 was not
precipitated in a Dada1 extract or by preimmune serum, dem-
onstrating that this interaction is specific and dependent on
ADA1. Two other proteins probed in this experiment, TBP
and TFIIB, did not coprecipitate with ADA1, indicating that
they either do not interact with ADA1 or that an interaction is
too weak to be detected.
To demonstrate that the other ADA gene products also
interact either directly or indirectly with ADA1, antibodies to
ADA2, GCN5, ADA5, and, as controls, to ADA1 and preim-
mune serum were cross-linked to protein A-Sepharose beads
and used in immunoprecipitation experiments. As shown in
Fig. 5C, antibodies to ADA2, GCN5, ADA5, and ADA1 but
not to preimmune serum were able to precipitate ADA1 from
wild-type extracts, demonstrating that there is an interaction
between all of the ADA gene products. As verification that the
protein coprecipitated by these antibodies is ADA1, the lower
blot of Fig. 5C demonstrates that the protein is not precipi-
tated from a Dada1 extract. These results suggest that ADA1,
ADA2, ADA3, GCN5, and ADA5 are all found in a single
complex.
DISCUSSION
We report here the cloning, sequencing, and characteriza-
tion of ADA1, which encodes a novel member of the ADA/
GCN5 complex. ADA1 encodes a 488-amino-acid protein.
ada1 mutants display defects in transcription similar to those of
ada5 mutants and broader than those found in ada2, ada3, and
gcn5 mutants. Notably, mutations in ADA2, ADA3, and GCN5
do not affect transcription from the ADH1 promoter, while
mutations in ADA1 and ADA5 decrease the activity of this
reporter approximately fivefold. Indeed, since the activator
that was used in the ADA screen, GAL4-VP16, was overex-
pressed by using the ADH1 promoter, it was initially thought
that ADA1 was totally unrelated to ADA2, ADA3, and GCN5
because resistance could arise from a reduction in the amount
of GAL4-VP16 produced. On the other hand, all ada mutants
display similar decreases in transcription from GCN4-depen-
dent promoters. Importantly, activity from the dAdT reporter
was not reduced in a Dada1 strain, demonstrating that not all
transcription is dependent on ADA1. It has been proposed that
FIG. 5. Coprecipitation experiments between ADA1 and other ADA pro-
teins. (A) Whole-cell extracts from BWG1-7a (WT) or 1-7aDada1 (Dada1)
strains were fractionated on a Bio-Rex 70 column as described in Materials and
Methods. Proteins were eluted stepwise in 250, 600 and 1,200 mM potassium
acetate. Then, 20 mg each of whole-cell extract (starting material), the flow-
through, and each of the elutions were assayed for ADA1 and ADA3 by Western
blot analysis. Recombinant ADA1 (rec ADA1) was used as a control in the
Dada1 blot to determine the migration of ADA1 by SDS-PAGE. The band in the
600 mM elution in the Dada1 extract is a background band that migrates slightly
above that of ADA1. (B) Immunoprecipitations were performed on 1 ml of the
600 mM elution from the wild-type (wt) and Dada1 extracts shown in panel A by
using either protein A-Sepharose beads cross-linked to ADA1 antibody (aADA1)
or preimmune serum (PI). Then, 100 ml of the 600 mM elution (START) of
wild-type and Dada1 extracts as well as the precipitations was subjected to
SDS-PAGE and immunoblotted with the antibodies to the indicated proteins
(ADA3, ADA1, TFIIB, and TBP). The band below ADA1 corresponds to an
uncross-linked immunoglobulin G heavy chain which was eluted off the beads
and which cross-reacts with the secondary antibody. (C) Immunoprecipitations
were performed on 1 ml of the 600 mM elution from the wild-type (wt) and the
Dada1 extracts shown in panel A. Protein A-Sepharose beads cross-linked to
preimmune serum (PI) and antibodies to ADA2 (aADA2), GCN5 (aGCN5),
ADA5 (aADA5), and ADA1 (aADA1) were used for immunoprecipitations.
Then, 250 ml of the 600 mM elution from the extracts (START) as well as from
each of the precipitations was subjected to SDS-PAGE and analyzed by Western
blotting for the presence of ADA1. As in panel B, the band below ADA1 in the
precipitation lanes corresponds to an immunoglobulin G heavy chain. Rec
ADA1 refers to 5 ng of recombinant ADA1.
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the dAdT UAS activates transcription because this DNA se-
quence by itself disrupts nucleosomes (31). It is possible that
disruption of chromatin by dAdT bypasses the need for the
histone acetyl transferase activity of the ADA/GCN5 complex
in transcription.
Two classes of ADA genes. The similarity in transcription
defects between Dada1 and Dada5 strains led us to test
whether the strains had other phenotypes in common. We have
determined that Dada1 strains are auxotrophic for inositol and
are Spt2, two phenotypes described for ada5 mutants (45).
Furthermore, both ADA1 and ADA5 are in the TBP class of
SPTs, not the histone class. This is in agreement with previous
genetic and biochemical data and suggests a link between the
functions of the ADA/GCN5 complex and TBP (2, 37). Con-
trols consisting of representative mutants of the ADA2, ADA3,
and GCN5 class of ADAs are neither auxotrophic for inositol
nor Spt2. Thus, the ADA genes can be separated into two
distinct classes based on three criteria: transcriptional report-
ers that are affected, inositol auxotrophy, and Spt phenotype.
The five ADA gene products form a complex. With two
different classes of ADA genes, it seemed possible that two
different complexes may be formed. Previously, it has been
shown that ADA2, GCN5, and ADA3 form a complex in vitro
(2, 29). Also, various individual interactions between these
three ADA proteins have been demonstrated in vivo (29, 38).
Therefore, it is clear that components of one of the classes
form a complex. Interestingly, an interaction between ADA3
and ADA5 has also been demonstrated (37), indicating a pos-
sible interaction between members of different classes of
ADAs. Here we present evidence that all five ADA proteins
bind together in a complex by two methods. First, we demon-
strate that the five proteins remain together throughout an
approximately 2,880-fold purification over four successive col-
umns. In each of these columns, the ADA proteins eluted with
identical profiles (Fig. 3 and 4) (56). Second, we demonstrate,
using immunoprecipitation experiments, specific interactions
between ADA1 and each of the other ADA proteins (Fig. 5).
These two lines of evidence, taken together, strongly support a
model in which all five ADA proteins form a complex in vivo.
The elution profile of the ADA proteins through the Super-
ose 6 column indicates that the complex migrates with a mo-
lecular mass of approximately 2 MDa. This is much larger than
the sum of the molecular masses of the five known individual
subunits, suggesting that there may be other components that
have yet to be identified or that the known components are
present as multimers. Many other transcription factors have
been shown to be associated in large-molecular-weight com-
plexes, such as the TFIID complex, the SWI/SNF complex, and
the holoenzyme complex. One possibility is that the ADA
proteins could be part of one of these complexes. However,
probing the partially purified ADA fractions with antibodies to
TBP, Pol II, SWI3, and various SRBs demonstrated that these
proteins do not peak with the ADA proteins (56). Thus, the
ADA/GCN5 complex may be distinct and novel.
In all the purification steps performed, all five ADA proteins
cofractionate. This cofractionation is not limited to the ADAs
in the 600 mM potassium acetate elution of the initial Bio-Rex
70 column but extends also to the ADAs in the flowthrough
and 1,200 mM potassium acetate elutions (28, 56). Thus, al-
though we cannot rule out the formal possibility that ADA1
and ADA5 may form an alternate complex without the other
ADAs, we have not found any evidence of this, and it seems
more likely that all five ADA proteins are always associated.
It has recently been shown that a Tetrahymena GCN5 com-
plex contains a protein that cross-reacts with antibody to
ADA1 (9). Also, human homologs of ADA2 and GCN5 have
been isolated, and these homologs have been demonstrated to
interact with each other (13). These data suggest that the
ADA/GCN5 complex is evolutionarily conserved.
One complex with two separate functions? As mentioned
before, it has been determined that GCN5 functions as a his-
tone acetyltransferase (10) and can acetylate free histone H3 in
vitro. However, it is unable to acetylate whole nucleosomes.
Thus, one function proposed for the other ADAs in the com-
plex is to alter the conformation of either GCN5 or of nucleo-
somes, allowing the acetylation of whole nucleosomes (47). We
have demonstrated here that there are at least five ADA pro-
teins in the ADA/GCN5 complex and that they can be sepa-
rated into two distinct classes. We propose that the ADA
proteins of one class, ADA2, ADA3, and GCN5, function
together to acetylate nucleosomes, resulting in the clearing
away of repressive nucleosomes from some promoters. The
ADAs of the other class, ADA1 and ADA5, have an additional
function. This is supported by the observation that ada1 and
ada5 mutants have more pronounced phenotypic defects than
ada2, ada3, and gcn5 mutants. If GCN5-dependent acetylation
of histones was the sole function of the ADA/GCN5 complex,
one would not expect to observe any ada mutants with pheno-
types more severe than those of Dgcn5 mutants.
The proposed second function of the ADA/GCN5 complex
has not been defined yet. One possibility is that GCN5 is not
the only histone acetyltransferase in the ADA complex and
that there is a second one that interacts with ADA1 and
ADA5. On the other hand, it is fascinating that both ADA1 and
ADA5, but not the other ADAs, are in the TBP class of SPTs.
Recently, it has been demonstrated that some strains with
mutations in SPT15, which encodes TBP, are resistant to
GAL4-VP16 toxicity (37). It is extremely interesting to specu-
late, therefore, that the function of this second class of ADAs
may be to interact with basal factors, possibly TBP. The ADA/
GCN5 complex may be brought to promoters through inter-
actions between activators and ADA2 (2, 39, 55) and ADA5
(37). Once there, the ADA2, ADA3, and GCN5 class of ADAs
may function to acetylate nucleosomes, opening up the pro-
moter region, while the ADA1 and ADA5 class of ADAs
recruit TBP and possibly other basal factors to bind to the
TATA box. The observation that Dada1 or Dada5 strains dis-
play broader defects than Dada2, Dada3, or Dgcn5 strains,
combined with the observation that Dada3 and Dada5 strains
do not display phenotypes more severe than Dada5 strains
(37), suggests the following. Disrupting a member of the
ADA2, ADA3, and GCN5 class of ADA will not disrupt the
activity of the ADA1 and ADA5 class, whereas disrupting
ADA1 or ADA5 may disrupt the activity of the entire ADA/
GCN5 complex.
It should be mentioned that TBP is not present in our
partially purified ADA fractions and is not immunoprecipi-
tated by ADA antibodies (Fig. 3 and 4). However, other groups
have demonstrated such interactions (2, 48), and it is possible
that TBP is not a stably bound component of the ADA/GCN5
complex but rather is only transiently associated, i.e., only
when bound to DNA or when activators are bound to the ADA
complex. Alternatively, it is possible that the ADAs in the
1,200 mM potassium acetate fraction from the Bio-Rex 70
column have different properties from the ADAs in the 600
mM fraction which we have been studying. Indeed, it has
recently been reported that several ADA/GCN5 complexes
may exist in yeast (48). It will be interesting to determine
whether the ADAs in the 1,200 mM potassium acetate fraction
may be bound to TBP or other basal factors.
3226 HORIUCHI ET AL. MOL. CELL. BIOL.
ACKNOWLEDGMENTS
We thank A. Koleske, D. Chao, C. Wilson, C. Hengartner, and R.
Young for sharing antibodies and for technical assistance. We also
thank A. Greenleaf and C. Peterson for sharing antisera and K. Kaplan
for assistance with the Sprint BIOCAD apparatus. We are grateful to
S. Roberts and F. Winston for strains, T. D. Fox and D. Allis for
sharing unpublished results, and D. McNabb for critical comments on
the manuscript. G.M. thanks C. Armstrong and S. Treadway for help
with the GCN5 antibody.
J.H. was an HHMI predoctoral fellow. This work was supported by
grant GM50207 from NIH to L.G.
REFERENCES
1. Alani, E., L. Cao, and N. Kleckner. 1987. A method for gene disruption that
allows repeated use of URA3 selection in the construction of multiply dis-
rupted yeast strains. Genetics 116:541–545.
2. Barlev, N. A., R. Candau, L. Wang, P. Darpino, N. Silverman, and S. L.
Berger. 1995. Characterization of physical interactions of the putative tran-
scriptional adaptor, ADA2, with acidic activation domains and TATA-bind-
ing protein. J. Biol. Chem. 270:19337–19344.
3. Berger, S. L., W. D. Cress, A. Cress, S. J. Triezenberg, and L. Guarente.
1990. Selective inhibition of activated but not basal transcription by the
acidic activation domain of VP16: evidence for transcriptional adaptors. Cell
61:1199–1208.
4. Berger, S. L., B. Pin˜a, N. Silverman, G. A. Marcus, J. Agapite, J. L. Regier,
S. J. Triezenberg, and L. Guarente. 1992. Genetic isolation of ADA2: a
potential transcriptional adaptor required for function of certain acidic ac-
tivation domains. Cell 70:251–265.
5. Brandl, C. J., A. M. Furlanetto, J. A. Martens, and K. S. Hamilton. 1993.
Characterization of NGG1, a novel yeast gene required for glucose repres-
sion of GAL4p-regulated transcription. EMBO J. 12:5255–5265.
6. Brandl, C. J., J. A. Martens, A. Margaliot, D. Stenning, A. M. Furlanetto, A.
Saleh, K. S. Hamilton, and J. Genereaux. 1996. Structure/functional prop-
erties of the yeast dual regulator protein NGG1 that are required for glucose
repression. J. Biol. Chem. 271:9298–9306.
7. Brownell, J. E., and C. D. Allis. 1995. An activity gel assay detects a single,
catalytically active histone acetyltransferase subunit in Tetrahymena macro-
nuclei. Proc. Natl. Acad. Sci. USA 92:6364–6368.
8. Brownell, J. E., and C. D. Allis. 1996. Special HATs for special occasions:
linking histone acetylation to chromatin assembly and gene activation. Curr.
Opin. Genet. Dev. 6:176–184.
9. Brownell, J. E., T. A. Ranalli, and C. D. Allis. Personal communication.
10. Brownell, J. E., J. Zhou, T. Ranalli, R. Kobayashi, D. G. Edmondson, S. Y.
Roth, and C. D. Allis. 1996. Tetrahymena histone acetyltransferase A: a
homolog to yeast Gcn5p linking histone acetylation to gene activation. Cell
84:843–851.
11. Cairns, B. R., Y.-J. Kim, M. H. Sayre, B. C. Laurent, and R. D. Kornberg.
1994. A multisubunit complex containing the SWI1/ADR6, SWI2/SNF2,
SWI3, SNF5, and SNF6 gene products isolated from yeast. Proc. Natl. Acad.
Sci. USA 91:1950–1954.
12. Candau, R., and S. L. Berger. 1996. Structural and functional analysis of
yeast putative adaptors. Evidence for an adaptor complex in vivo. J. Biol.
Chem. 271:5237–5245.
13. Candau, R., P. A. Moore, L. Wang, N. Barlev, C. Y. Ying, C. A. Rosen, and
S. L. Berger. 1996. Identification of human proteins functionally conserved
with the yeast putative adaptors ADA2 and GCN5. Mol. Cell. Biol. 16:593–
602.
14. Cote, J., J. Quinn, J. L. Workman, and C. L. Peterson. 1994. Stimulation of
GAL4 derivative binding to nucleosomal DNA by the yeast SWI/SNF com-
plex. Science 265:53–60.
15. Dynlacht, B. D., T. Hoey, and R. Tjian. 1991. Isolation of coactivators
associated with the TATA-binding protein that mediate transcriptional ac-
tivation. Cell 66:563–576.
16. Eisenmann, D. M., K. M. Arndt, S. L. Ricupero, J. W. Rooney, and F.
Winston. 1992. SPT3 interacts with TFIID to allow normal transcription in
Saccharomyces cerevisiae. Genes Dev. 6:1319–1331.
17. Eisenmann, D. M., C. Chapon, S. M. Roberts, C. Dollard, and F. Winston.
1994. The Saccharomyces cerevisiae SPT8 gene encodes a very acidic protein
that is functionally related to SPT3 and TATA-binding protein. Genetics
137:647–657.
18. Forsberg, S. L., and L. Guarente. 1989. Identification and characterization of
HAP4: a third component in the CCAAT-bound HAP2/HAP3 heteromer.
Genes Dev. 3:1166–1178.
19. Fox, T. D. Personal communication.
20. Georgakopoulos, T., N. Gounalaki, and G. Thireos. 1995. Genetics evidence
for the interaction of the yeast transcriptional coactivator proteins GCN5
and ADA2. Mol. Gen. Genet. 246:723–728.
21. Georgakopoulos, T., and G. Thireos. 1992. Two distinct yeast transcriptional
activators require the function of the GCN5 protein to promote normal
levels of transcription. EMBO J. 11:4145–4152.
22. Guarente, L., B. Lalonde, P. Gifford, and E. Alani. 1984. Distinctly regulated
tandem upstream activation sites mediate catabolite repression of the CYC1
gene. Cell 36:503–511.
23. Guthrie, C., and G. R. Fink. 1991. Guide to yeast genetics and molecular
biology. Methods Enzymol. 194:835.
24. Harlow, E., and D. Lane. 1988. Antibodies: a laboratory manual. Cold Spring
Harbor Laboratory, Cold Spring Harbor, N.Y.
25. Hengartner, C. J., C. M. Thompson, J. Zhang, D. M. Chao, S. M. Liao, A. J.
Koleske, S. Okamura, and R. A. Young. 1995. Association of an activator
with an RNA polymerase II holoenzyme. Genes Dev. 9:897–910.
26. Hinnebusch, A. G., G. Lucchini, and G. R. Fink. 1985. A synthetic HIS4
regulatory element confers general amino acid control on the cytochrome c
gene (CYC1) of yeast. Proc. Natl. Acad. Sci. USA 82:495–502.
27. Hirschhorn, J. N., S. A. Brown, C. D. Clark, and F. Winston. 1992. Evidence
that SNF2/SWI2 and SNF5 activate transcription in yeast by altering chro-
matin structure. Genes Dev. 6:2288–2298.
28. Horiuchi, J., and L. Guarente. Unpublished results.
29. Horiuchi, J., N. Silverman, G. A. Marcus, and L. Guarente. 1995. ADA3, a
putative transcriptional adaptor, consists of two separable domains and in-
teracts with ADA2 and GCN5 in a trimeric complex. Mol. Cell. Biol. 15:
1203–1209.
30. Ireton, K., D. Z. Rudner, K. J. Siranosian, and A. D. Grossman. 1993.
Integration of multiple developmental signals in Bacillus subtilis through the
Spo0A transcription factor. Genes Dev. 7:283–294.
31. Iyer, V., and K. Struhl. 1995. Poly(dA:dT), a ubiquitous promoter element
that stimulates transcription via its intrinsic DNA structure. EMBO J. 14:
2570–2579.
32. Kelleher, R. J. I., P. M. Flanagan, and R. D. Kornberg. 1990. A novel
mediator between activator proteins and the RNA polymerase II transcrip-
tion apparatus. Cell 61:1209–1215.
33. Knaus, R., R. Pollock, and L. Guarente. 1996. Yeast SUB1 is a suppressor of
TFIIB mutations and has homology to the human coactivator PC4. EMBO
J. 15:101–108.
34. Koleske, A. J., S. Buratowski, M. Nonet, and R. A. Young. 1992. A novel
transcription factor reveals a functional link between the RNA polymerase II
CTD and TFIID. Cell 69:883–894.
35. Koleske, A. J., and R. A. Young. 1994. An RNA polymerase II holoenzyme
responsive to activators. Nature 368:466–469.
36. Lue, N. F., A. R. Buchman, and R. D. Kornberg. 1989. Activation of yeast
RNA polymerase II promoters by a thymidine-rich upstream element in
vitro. Proc. Natl. Acad. Sci. USA 86:486–490.
37. Marcus, G. A., J. Horiuchi, N. Silverman, and L. Guarente. 1996. ADA5/
SPT20 links the ADA and SPT genes, which are involved in yeast transcrip-
tion. Mol. Cell. Biol. 16:3197–3205.
38. Marcus, G. A., N. Silverman, S. L. Berger, J. Horiuchi, and L. Guarente.
1994. Functional similarity and physical association between GCN5 and
ADA2: putative transcriptional adaptors. EMBO J. 13:4807–4815.
39. Melcher, K., and S. A. Johnston. 1995. GAL4 interacts with TATA-binding
protein and coactivators. Mol. Cell. Biol. 15:2839–2848.
40. Peterson, C. L., A. Dingwall, and M. P. Scott. 1994. Five SWI/SNF gene
products are components of a large multisubunit complex required for tran-
scriptional enhancement. Proc. Natl. Acad. Sci. USA 91:2905–2908.
41. Peterson, C. L., W. Kruger, and I. Herskowitz. 1991. A functional interaction
between the C-terminal domain of RNA polymerase II and the negative
regulator SIN1. Cell 64:1135–1143.
42. Pfeifer, K., B. Arcangioli, and L. Guarente. 1987. Yeast HAP1 activator
competes with the factor RC2 for binding to the upstream activation site
UAS1 of the CYC1 gene. Cell 49:9–18.
43. Pin˜a, B., S. Berger, G. A. Marcus, N. Silverman, J. Agapite, and L. Guarente.
1993. ADA3: a gene, identified by resistance to GAL4-VP16, with properties
similar to and different from those of ADA2. Mol. Cell. Biol. 13:5981–5989.
44. Pugh, B. F., and R. Tjian. 1990. Mechanism of transcriptional activation by
Sp1: evidence for coactivators. Cell 61:1187–1197.
45. Roberts, S. M., and F. Winston. 1996. SPT20/ADA5 encodes a novel protein
functionally related to the TATA-binding protein and important for tran-
scription in Saccharomyces cerevisiae. Mol. Cell. Biol. 16:3206–3213.
46. Rose, M., and D. Botstein. 1983. Structure and function of the yeast URA3
gene. Differentially regulated expression of hybrid beta-galactosidase from
overlapping coding sequences in yeast. J. Mol. Biol. 170:883–904.
47. Roth, S. Y., and C. D. Allis. 1996. The subunit exchange model of histone
acetylation. Trends Cell Biol. 6:371–375.
48. Saleh, A., V. Lang, R. Cook, and C. Brandl. 1997. Identification of native
complexes containing the yeast coactivator/repressor proteins NGG1/ADA3
and ADA2. J. Biol. Chem. 272:5571–5578.
49. Sanger, F., S. Nicklen, and A. R. Coulson. 1977. DNA sequencing with
chain-terminating inhibitors. Proc. Natl. Acad. Sci. USA 74:5463–5467.
50. Santangelo, G. M., J. Tornow, C. S. McLaughlin, and K. Moldave. 1988.
Properties of promoters cloned randomly from the Saccharomyces cerevisiae
genome. Mol. Cell. Biol. 8:4217–4224.
51. Sauer, F., S. K. Hansen, and R. Tjian. 1995. Multiple TAFIIs directing
synergistic activation of transcription. Science 270:1783–1788.
52. Sayre, M. H., H. Tschochner, and R. D. Kornberg. 1992. Reconstitution of
VOL. 17, 1997 ADA1 AND THE ROLES OF THE ADA/GCN5 COMPLEX 3227
transcription with five purified initiation factors and RNA polymerase II
from Saccharomyces cerevisiae. J. Biol. Chem. 267:23376–23382.
53. Sherman, F., G. R. Fink, and J. B. Hicks. 1986. Methods in yeast genetics.
Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.
54. Sikorski, R. S., and P. Hieter. 1989. A system of shuttle vectors and yeast
host strains designed for efficient manipulation of DNA in Saccharomyces
cerevisiae. Genetics 122:19–27.
55. Silverman, N., J. Agapite, and L. Guarente. 1994. Yeast ADA2 protein binds
to the VP16 protein activation domain and activates transcription. Proc.
Natl. Acad. Sci. USA 91:11665–11668.
56. Silverman, N., and L. Guarente. Unpublished results.
57. Swanson, M. S., and F. Winston. 1992. SPT4, SPT5 and SPT6 interactions:
effects on transcription and viability in Saccharomyces cerevisiae. Genetics
132:325–336.
58. Thompson, C. M., A. J. Koleske, D. M. Chao, and R. A. Young. 1993. A
multisubunit complex associated with the RNA polymerase II CTD and
TATA-binding protein in yeast. Cell 73:1361–1375.
59. Thut, C. J., J. L. Chen, R. Klemm, and R. Tjian. 1995. p53 transcriptional
activation mediated by coactivators TAFII40 and TAFII60. Science 267:100–
104.
60. Wilson, C. J., D. M. Chao, A. N. Imbalzano, G. R. Schnitzler, R. E. Kingston,
and R. A. Young. 1996. RNA polymerase II holoenzyme contains SWI/SNF
regulators involved in chromatin remodeling. Cell 84:235–244.
61. Winston, F. 1992. Analysis of SPT genes: a genetic approach toward analysis
of TFIID, histones, and other transcription factors of yeast, p. 1271–1293. In
S. L. McKnight and K. R. Yamamoto (ed.), Transcriptional regulation. Cold
Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
3228 HORIUCHI ET AL. MOL. CELL. BIOL.
